Farnum Rhonda 4

What Happened
Rhonda Farnum, SVP, Commercial & Medical Affairs at Theravance Biopharma (TBPH), disposed of a total of 13,314 shares in open-market sales on 2026-06-15. The filing reports three trades: 3,329 shares at $16.39 ($54,563), 3,328 shares at $16.38 ($54,525), and 6,657 shares at $16.39 ($109,079), for aggregate proceeds of approximately $218,167. The filing notes these were executed under a 10b5‑1 plan dated 09/03/2025.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (filed within the SEC’s typical 2-business‑day reporting window).
• Reported trades: 3,329 @ $16.39 ($54,563); 3,328 @ $16.38 ($54,525); 6,657 @ $16.39 ($109,079).
• Footnote: trades executed in multiple fills at prices ranging $16.21–$16.61; prices shown are weighted averages (F1).
• Shares owned after transaction: Not disclosed in the filing.
• Plan/authorization: Sales executed pursuant to a 10b5‑1 trading plan (dated 09/03/2025).
• No indication of option exercises, gifts, or tax‑withholding shares in this filing.

Context: These are routine sales under a pre-arranged 10b5‑1 plan, which many insiders use to sell shares on a set schedule and which generally don’t indicate a change in insider sentiment. For retail investors, purchases by insiders tend to be more informative than routine sales; this transaction is modest in size (~$218k) relative to many institutional moves.